OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD
Ankelien Duchow, Judith Bellmann‐Strobl, Tim Friede, et al.
Annals of Neurology (2023) Vol. 95, Iss. 4, pp. 720-732
Open Access | Times Cited: 24
Ankelien Duchow, Judith Bellmann‐Strobl, Tim Friede, et al.
Annals of Neurology (2023) Vol. 95, Iss. 4, pp. 720-732
Open Access | Times Cited: 24
Showing 24 citing articles:
NMOSD and MOGAD: an evolving disease spectrum
Akiyuki Uzawa, Frederike Cosima Oertel, Masahiro Mori, et al.
Nature Reviews Neurology (2024)
Closed Access | Times Cited: 11
Akiyuki Uzawa, Frederike Cosima Oertel, Masahiro Mori, et al.
Nature Reviews Neurology (2024)
Closed Access | Times Cited: 11
Clinical characteristics of late-onset neuromyelitis optica spectrum disorder in China
Qingli Sun, Jian Li, Danyang Tian
Journal of Clinical Neuroscience (2025) Vol. 135, pp. 111137-111137
Open Access | Times Cited: 1
Qingli Sun, Jian Li, Danyang Tian
Journal of Clinical Neuroscience (2025) Vol. 135, pp. 111137-111137
Open Access | Times Cited: 1
Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders
Paolo Preziosa, Maria Pia Amato, Luca Battistini, et al.
Journal of Neurology (2024) Vol. 271, Iss. 7, pp. 3879-3896
Closed Access | Times Cited: 6
Paolo Preziosa, Maria Pia Amato, Luca Battistini, et al.
Journal of Neurology (2024) Vol. 271, Iss. 7, pp. 3879-3896
Closed Access | Times Cited: 6
Soluble biomarkers for Neuromyelitis Optica Spectrum Disorders: a mini review
Rachel E. Rodin, Tanuja Chitnis
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 4
Rachel E. Rodin, Tanuja Chitnis
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 4
Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicators
Michael Hecker, Brit Fitzner, Isis Ludwig‐Portugall, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Michael Hecker, Brit Fitzner, Isis Ludwig‐Portugall, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study
Romain Marignier, Javier Villacieros‐Álvarez, Carmen Espejo, et al.
Journal of Neurology Neurosurgery & Psychiatry (2025), pp. jnnp-335137
Closed Access
Romain Marignier, Javier Villacieros‐Álvarez, Carmen Espejo, et al.
Journal of Neurology Neurosurgery & Psychiatry (2025), pp. jnnp-335137
Closed Access
Comparison of treatment efficacy and cost-effectiveness of rituximab and oral agents among patients with neuromyelitis optica spectrum disorders: a population-based cohort study
Hye Lim Lee, Minwoong Kang, Jin Myoung Seok, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
Hye Lim Lee, Minwoong Kang, Jin Myoung Seok, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
The nomogram model predicts relapse risk in myelin oligodendrocyte glycoprotein antibody-associated disease: a single-center study
Jun Cheng, Zhuoran Wang, J. Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Jun Cheng, Zhuoran Wang, J. Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Optic Neuritis
Eric Eggenberger
CONTINUUM Lifelong Learning in Neurology (2025) Vol. 31, Iss. 2, pp. 407-435
Closed Access
Eric Eggenberger
CONTINUUM Lifelong Learning in Neurology (2025) Vol. 31, Iss. 2, pp. 407-435
Closed Access
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study
Pakeeran Siriratnam, Saif Huda, Anneke van der Walt, et al.
Journal of Neurology (2025) Vol. 272, Iss. 5
Open Access
Pakeeran Siriratnam, Saif Huda, Anneke van der Walt, et al.
Journal of Neurology (2025) Vol. 272, Iss. 5
Open Access
Brain health – time matters: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and related conditions. 2024 report
Helmut Butzkueven, Gavin Giovannoni, Sofia Arkelsten, et al.
Multiple Sclerosis and Related Disorders (2025), pp. 106456-106456
Closed Access
Helmut Butzkueven, Gavin Giovannoni, Sofia Arkelsten, et al.
Multiple Sclerosis and Related Disorders (2025), pp. 106456-106456
Closed Access
MOG Antibody Disease: Nuances in Presentation, Diagnosis, and Management
Kelsey Stefan, John R. Ciotti
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 8, pp. 219-232
Closed Access | Times Cited: 2
Kelsey Stefan, John R. Ciotti
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 8, pp. 219-232
Closed Access | Times Cited: 2
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
Pakeeran Siriratnam, Paul G. Sanfilippo, Anneke van der Walt, et al.
Journal of Neurology Neurosurgery & Psychiatry (2024), pp. jnnp-334090
Closed Access | Times Cited: 2
Pakeeran Siriratnam, Paul G. Sanfilippo, Anneke van der Walt, et al.
Journal of Neurology Neurosurgery & Psychiatry (2024), pp. jnnp-334090
Closed Access | Times Cited: 2
Efficacy and safety of apheresis therapy in AQP 4 antibody‐positive NMOSD attack: A propensity score‐matched cohort study
Yun Xu, Huabing Wang, Tian Song, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 5
Open Access | Times Cited: 1
Yun Xu, Huabing Wang, Tian Song, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 5
Open Access | Times Cited: 1
Myelin oligodendrocyte glycoprotein antibody-associated disease
Andreas Winkelmann, Paulus Rommer, Michael Hecker, et al.
DGNeurologie (2024) Vol. 7, Iss. 5, pp. 371-375
Closed Access | Times Cited: 1
Andreas Winkelmann, Paulus Rommer, Michael Hecker, et al.
DGNeurologie (2024) Vol. 7, Iss. 5, pp. 371-375
Closed Access | Times Cited: 1
Efficacy of tocilizumab in highly relapsing MOGAD with an inadequate response to intravenous immunoglobulin therapy: A case series
You-Ri Kang, Ki Hoon Kim, Jae‐Won Hyun, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 91, pp. 105859-105859
Closed Access | Times Cited: 1
You-Ri Kang, Ki Hoon Kim, Jae‐Won Hyun, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 91, pp. 105859-105859
Closed Access | Times Cited: 1
Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks
Carolin Schwake, Theodoros Ladopoulos, Vivien Häußler, et al.
Journal of Neurology Neurosurgery & Psychiatry (2024), pp. jnnp-334863
Open Access | Times Cited: 1
Carolin Schwake, Theodoros Ladopoulos, Vivien Häußler, et al.
Journal of Neurology Neurosurgery & Psychiatry (2024), pp. jnnp-334863
Open Access | Times Cited: 1
Neue Therapieoptionen bei Neuromyelitis- optica-Spektrum-Erkrankung
Agni-Maria Konitsioti, Sarah Laurent, Gereon R. Fink, et al.
InFo Neurologie + Psychiatrie (2024) Vol. 26, Iss. 9, pp. 30-41
Closed Access
Agni-Maria Konitsioti, Sarah Laurent, Gereon R. Fink, et al.
InFo Neurologie + Psychiatrie (2024) Vol. 26, Iss. 9, pp. 30-41
Closed Access
Early Rituximab versus Escalating Therapy in Neuromyelitis Optica: A Cost and Quality of Life Analysis
Guilherme Diogo Silva, Samira Luísa Apóstolos‐Pereira, Mateus Boaventura de Oliveira, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 92, pp. 106160-106160
Closed Access
Guilherme Diogo Silva, Samira Luísa Apóstolos‐Pereira, Mateus Boaventura de Oliveira, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 92, pp. 106160-106160
Closed Access
The atypical faces of optic neuritis: neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease
Sabrina Poonja, Natthapon Rattanathamsakul, John J. Chen
Current Opinion in Neurology (2024) Vol. 38, Iss. 1, pp. 96-104
Closed Access
Sabrina Poonja, Natthapon Rattanathamsakul, John J. Chen
Current Opinion in Neurology (2024) Vol. 38, Iss. 1, pp. 96-104
Closed Access
Advances in Diagnosis and Management of Atypical Demyelinating Diseases
Spencer Hutto, Julien J. Cavanagh
Medical Clinics of North America (2024) Vol. 109, Iss. 2, pp. 425-441
Closed Access
Spencer Hutto, Julien J. Cavanagh
Medical Clinics of North America (2024) Vol. 109, Iss. 2, pp. 425-441
Closed Access
Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder
Bo Chen, Anna Francis, Susan M. Cooper, et al.
Neurology (2024) Vol. 104, Iss. 1
Closed Access
Bo Chen, Anna Francis, Susan M. Cooper, et al.
Neurology (2024) Vol. 104, Iss. 1
Closed Access
Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision
Mihaela Nicolescu, Vivien Häußler, Friedemann Paul, et al.
Journal of Neurology (2024) Vol. 272, Iss. 1
Closed Access
Mihaela Nicolescu, Vivien Häußler, Friedemann Paul, et al.
Journal of Neurology (2024) Vol. 272, Iss. 1
Closed Access
Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD
Vivien Häußler, Corinna Trebst, Daniel Engels, et al.
Journal of Neurology Neurosurgery & Psychiatry (2024), pp. jnnp-334764
Closed Access
Vivien Häußler, Corinna Trebst, Daniel Engels, et al.
Journal of Neurology Neurosurgery & Psychiatry (2024), pp. jnnp-334764
Closed Access
